Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 and diabetes: A bidirectional relationship

M.M. Lima-Martínez, C. Carrera Boada, M.D. Madera-Silva, W. Marín, M. Contreras

Abstract  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causal agent of coronavirus disease 2019 (COVID-19). Diabetes is one of the most frequent comorbidities in people with COVID-19 with a prevalence that varies between 7 and 30%. Diabetics infected with SARS-CoV-2 have a higher rate of hospital admission, severe pneumonia, and higher mortality compared to non-diabetic subjects. Chronic hyperglycemia can compromise innate and humoral immunity. Furthermore, diabetes is associated with a low-grade chronic inflammatory state that favours the development of an exaggerated inflammatory response and therefore the appearance of acute respiratory distress syndrome. Recent evidence has shown that SARS-CoV-2 is also capable of causing direct damage to the pancreas that could worsen hyperglycemia and even induce the onset of diabetes in previously non-diabetic subjects. Therapeutic strategies should be aimed at facilitating patient access to the healthcare system. Control of blood glucose and comorbidities must be individualised in order to reduce the incidence of complications and decrease the burden on health systems. In this article we will review the pathophysiological mechanisms that explain the bidirectional relationship between COVID-19 and diabetes mellitus, its implication in the prognosis and management of hyperglycemia in this group of patients.

© 2021 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Arteriosclerosis.
Introduction

In December 2019 an acute respiratory disease outbreak started in China, characterised by fever, a dry cough and difficulty in breathing. One month later this was identified as a new coronavirus which was termed coronavirus 2 of the severe, acute respiratory syndrome (SARS-CoV-2), the causal agent of the disease from coronavirus 2019 (COVID-19).1

In general, people with diabetes are at greater risk of developing complications when they present with COVID-19.2,3 In Italy over two thirds of deaths associated with COVID-19 were observed in diabetic patients.4 This relationship between diabetes and mortality also appeared in previous epidemics caused by other coronavirus, such as that of the SARS in 2002 and the Middle East respiratory syndrome (MERS) in 2012.5

The development of diabetes in patients infected with SARS-CoV-2 has also been described, and it is therefore possible that SARS-CoV-2 may lead to changes in the metabolism of glucose which may lead to the appearance of diabetes mellitus.6 In this article we will review the pathophysiological mechanisms which explain the bidirectional relationship between COVID-19 and diabetes mellitus.

Diabetes mellitus as a risk factor for COVID-19

Diabetics infected with SARS-CoV-2 have a higher ratio of hospital admission, severe pneumonia and greater mortality compared with non diabetic subjects infected with SARS-CoV-2.2,3 In fact, diabetes is a factor of bad prognosis in COVID-19, since a recent meta-analysis showed that diabetes increases by 2.3 times the risk of severity, and 2.5 times the risk of the COVID-19-associated death.

Acute respiratory distress syndrome (ARDS) is the main cause of death by COVID-19 and occurs as a consequence of an exaggerated inflammatory response leading to the release of pro-inflammatory cytokines such as interleukins (IL) and tumoral necrosis factor-alpha.7 Toll-like receptors (TLR) are a family of proteins which act as sensors and help the immune system to discriminate between its own and foreign elements. SARS-CoV-1 and presumably SARS-CoV-2 interact with TLR in the host cell membrane and increase the expression of the primary response gene of myeloid (88 (MyD88) differentiation. This, in turn, activates the nuclear factor kappa beta, finally provoking an inflammatory cascade which increases lung damage.8

For its part, chronic hyperglycaemia may compromise innate immunity and humoral immunity. Diabetes is also associated with a chronic low grade inflammatory status which affects the regulation of glucose and the parietal sensitivity to insulin.9 In diabetic patients infected with SARS-CoV-2 an increase in IL-6 and reactive C protein (RCP) levels were in evidence, resulting in the actual pro-inflammatory status of the diabetes to promote the torment of cytokines and the systemic inflammatory response accompanying ARDS in patients with COVID-19.10

SARS-CoV-2 as a diabetogenic agent

Renin-angiotensin system

The renin-angiotensin system (RAS) is an elegant cascade of vasoactive peptides which orchestrate key processes in human physiology. The angiotensinogen produced in the liver is concealed by the action of the renin in a decapeptide called angiotensin (Ang) I and this in turn is converted by the angiotensin converting enzyme (ACE) into an octapeptide called Ang II which when acting on the Ang type I receptor (AT1-R), produces vasoconstrictor and oxidative effects and in the lungs induces contraction of the bronchial smooth muscle, a proliferation of fibroblasts, apoptosis of alveolar epithelial cells and increases vascular permeability.11,12

Furthermore, ACE2 is able to hydrolyze the Ang I and generate Ang (1–9); however, its catalytic activity is 400 times higher on Ang II and carries with it the formation of Ang (1–7) with vasodilation properties through the Mas (MAS-R).12
Figure 1  Duality of the renin-angiotensin (Ang.) system. When the angiotensin II (Ang II) acts on the type 1 receptor of Ang (AT1-R) it causes vasoconstrictor and oxidative effects, and induces fibrosis. The angiotensin converting enzyme 2 (ACE2) converts the Ang II into Ang (1–7) with vasodilatory, antioxidant and antifibrosis properties through the Mas receptor (MAS-R).

Figure 2  Mechanism of cellular infection of SARS-CoV-2. Structurally SARS-CoV-2 expresses a protein called protein S which binds with high affinity to the extracellular domain of the angiotensin converter 2 (ACE2) provoking the fusion of the membrane and the internalisation on the virus by endocytosis. This results in a loss of the ACE2 on the cell surface and also the entry of the virus allows for its replication.

receptor. Thus, the RAS functions as a dual endocrine system whereby the vasoconstrictor/proliferative actions and the vasodilatation/anti-proliferative actions are regulated by a balance between ACE and ACE2 (Fig. 1).

Cellular infection mechanism of SARS-CoV-2

Viral infections depend on entry of the virus into the cell and the use of the cellular host mechanisms to replicate multiple copies which go on to infect more cells. Coronavirus SARS-CoV-1 and SARS-CoV-2 enter the host cells using the ACE2 as a functional receptor. ACE2 is expressed in alveolar epithelial cells type 1 and type 2 and has 2 fractions: one soluble and one bound to the membrane.13

SARS-CoV-1 and SARS-CoV-2 express a protein in their structure called protein S, which contains a region of union that binds with high affinity to the extracellular domain of ACE2 leading to the fusion of the membrane and the internalisation of the virus by endocytosis (Fig. 2).14 The internalisation of the ACE2 by SARS-CoV-2 results in a loss
of the ACE2 in the surface area of the cell and therefore avoids degradation of the Ang II in Ang (1–7), which could contribute to the lung damage and fibrosis associated with COVID-19.\textsuperscript{15}

**SARS-CoV-2 and the pancreas**

Many viruses, such as Coxsackie B, enterovirus, rubeola, cytomegalovirus, Epstein–Barr virus and the varicela-zoster virus, have been implicated in the development of diabetes type 1.\textsuperscript{16} In fact, there is serological evidence of infection and isolation of the virus in the pancreas in patients with recent onset diabetes, and it is therefore possible that some viruses may act as diabetogenic agents.\textsuperscript{16}

It has recently been demonstrated that expression of ACE2 in the pancreas (mainly in islet cells) is even higher than in the lungs, and it is therefore possible that SARS-CoV-2 may bind to this receptor and enter the β cells of the pancreas, producing cellule dysfunction with acute hyperglycaemia (Fig. 3).\textsuperscript{17}

It is of note that only 1–2% of patients with mild infection by COVID-19 present with pancreatic lesions, whilst 17% of patients with severe cases present with pancreatic lesions, and this may emphasize the systemic inflammatory response and thereby accelerated the appearance of ARDS.\textsuperscript{12}

**Therapeutic considerations in the management of diabetic patients with COVID-19**

**The impact of oral hypoglycaemics in COVID-19**

Appropriate control of hyperglycaemia has been shown to lead to a lower rate of adverse events in patients with diabetes mellitus and COVID-19.\textsuperscript{18} Metformin is the first line drug in the management of diabetes type 2 and improves sensitivity to insulin through the activation of the AMP dependent protein (AMPK) in the liver.\textsuperscript{19} It has been suggested that metformin could be useful in COVID-19 because activation of AMPK leads to the phosphorylation of ACE2 and therefore generates functional changes which reduce the binding of the SARS-CoV-2 to the receptor.\textsuperscript{20} In contrast, the agonists of the peptide receptor similar to glucagon type 1 and the inhibitors of the co-transporter of type 2 sodium glucose may induce an over expression of ACE2, and they therefore may be inadequate in diabetic patients infected with SARS-CoV-2. However, they have a proven benefit in the prevention of cardiovascular and renal disease, and should therefore not be ruled out.\textsuperscript{21} Recently, it has been described that, based on its immunomodulator effect, the inhibitor of dipeptidyl peptidase 4 may reduce the severity of infection by SARS-CoV-2\textsuperscript{22} and the thiazolidinediones are able to reduce the production of pro-inflammatory cytokines, such as that of IL-6, which may improve the prognosis of diabetic patients infected with SARS-CoV-2.\textsuperscript{22}

**Factors impacting metabolic control during the COVID-19 pandemic**

Diabetic patients are more susceptible to developing psychological stress, anxiety and depression.\textsuperscript{23} In diabetics stress is associated with a poorer metabolic control, which includes a higher level of glucosylated haemoglobin, a higher body mass index and raised blood pressure.\textsuperscript{24}

The current scenario of the pandemic, even in non infected subjects, may promote the deterioration of metabolic control through the difficulties of access to the healthcare system, the lack of physical activity and the increase in stress associated with lockdown. Therapeutic tragedies should be aimed at facilitating access to the
healthcare system through telemedicine so as to advise patients on how to adapt treatment, or on any other medical situation to guide patients and carers in the control of diabetes, so as to prevent hospitalisation (Table 1). Telemedicine in this context, apart from distanced medical care, would allow for strengthening the education of the diabetic patient, increasing medical education and exchanging information between specialists and even promoting clinical research with other healthcare centres.

### Table 1  Outpatient management of patients with diabetes mellitus and COVID-19.

| Measures                                                                 |
|--------------------------------------------------------------------------|
| Prevention of the infection                                              |
| Healthy lifestyle                                                        |
| General measures for improving the control of diabetes                  |
| Treatment of hyperglycaemia                                              |
| Treatment of comorbidities                                              |
| Healthcare support                                                       |

**ADA**: American Association of Diabetes; **ALAD**: Latin American Diabetes Association; **COVID-19**: coronavirus disease 2019; **EASD**: European Association for the Study of Diabetes; **HbA1c**: glycosated haemoglobin A1c; **PAHO**: Pan-American Health Organisation; **VSEM**: Venezuelan Society of Endocrinology and Metabolism; **WHO**: World Health Organisation.

### Table 2  Special considerations of the drugs for diabetes mellitus in COVID-19.

| Drug          | Considerations in COVID-19                                                                 |
|---------------|-------------------------------------------------------------------------------------------|
| Metformin     | Risk of lactic acidosis especially in renal patients, hepatic patients or if dehydration takes place. Avoid in severely ill patients. |
| ISGLT2        | Increased risk of dehydration, deterioration of renal function and ketoadiposis. Suspend in severely ill patient. |
| GLP-1 ARs     | Potential gag reflex. Monitor hydration.                                                    |
| IDPP-4        | In general, quite safe                                                                     |
| Sulfonylureas | High risk of hypoglycaemias. Moderate risk                                                 |
| Insulin       | Drug of choice in diabetes type 1 and decompensated type 2. Drug of choice in severe diabetics or with COVID-19 complications. Need for very high doses in some cases. |

**COVID-19**: coronavirus disease 2019; **GLP-1 ARs**: glucagon-like peptide-1 receptor agonists; **IDPP-4**: Dipeptidyl-4 inhibitors; **ISGLT2**: sodium-glucose cotransporter 2 inhibitors.

Management of diabetic patients with COVID-19

Treatment of diabetics infected with SARS-CoV-2 is basically the same as usual, but it is important to make certain considerations. If the person is asymptomatic and maintains a good glycaemic control, no changes to their medication should be made. If the diabetic contracts COVID-19 and it develops into a mild infection, with no complications, a simple adjustment to medication according to the directives of glycaemic monitoring could be sufficient. Where the evolution of the condition is severe, and breathing difficulty ensues or they are referred for hospitalisation, treatment must be reassessed, taking into account several special considerations for each drug (Table 2). Severe cases must be treated with insulin. The most effective and safest insulin administration guidelines are continuous intravenous administration in critical patients and the administration of insulin in baseline-bolus-correction factor guideline, adapted to type of nutrition in non critical patients.

Controversy exists regarding the glycaemic control goal in diabetics with COVID-19, and it should therefore be individualised. In diabetic patients with mild to moderate infection from COVID-19 who are not hospitalised, a goal of 72–144 mg/dl has been proposed and in hospitalised patients that of 72–180 mg/dl (Fig. 4). However, specific treatment of COVID-19 is similar in diabetics and non diabetics. Given the higher frequency of severe progression in hyperglycaemic conditions, a more intensive approach in patients with diabetes is accepted.

High blood pressure management

Appropriate management of all comorbidities presented is important. In particular, the management of blood pressure is key in diabetics with COVID-19. Controversy arises regarding the use of ACE inhibitors and angiotensin receptor blockers (ATB) in patients with COVID-19, since these drugs may increase the expression of the ACE2 and there-
fore facilitate the virus entering into the cells.\textsuperscript{13,15} Despite this, several scientific societies and the European Medicines Agency have highlighted that there is insufficient evidence to justify the omission of these drugs in patients with COVID-19. Furthermore, recent studies have proven drug safety and even a potential benefit with the use of them.\textsuperscript{27,28}

Anticoagulation in the diabetic with COVID-19

Inflammation markers (RCP, erythrocyte sedimentation rate, IL-1, IL-6, ferritin) and hypercoagulability markers (D-dimer) are usually higher in patients with diabetes mellitus. This rationally supports the use of anti-inflammatory drugs and cytokine blockers, many of them experimental, with compassionate purposes in diabetic patients.

Diabetic patients have a propensity to develop thrombosis and in the context of infection by SARS-CoV-2 have a higher risk of thromboembolic events, which could justify treatment with anticoagulants.\textsuperscript{29} In diabetic patients hospitalised due to COVID-19 the use of prophylactic doses of low molecular weight heparin is suggested in the absence of contraindications (active bleeding or a platelet count of $<25 \times 10^9/\text{l}$), with an adjustment of dose for patients with frank elevation of D-dimer and those who present with criteria of severity. The studies derived from COVID-19 use 40–60 mg/day of enoxaparin for at least 7 days. The use of low molecular weight heparin reduces the generation of thrombin, has anti-inflammatory properties and reduces the appearance of a venous thromboembolic event.\textsuperscript{30}

Conclusions

There is a bidirectional relationship between COVID-19 and diabetes mellitus. On the one hand, people with diabetes have a higher risk of developing complications when they present with COVID-19 and, on the other, SARS-CoV-2 could act as a diabetogenic agent on binding to the ACE2 in beta cells of the pancreas, causing acute dysfunction and changes to glucose. Up until now, no clear data has existed on the impact of this pandemic on chronic complications associated with diabetes; however, it is essential to optimise the metabolic management of patients in order to improve prognosis and reduce the healthcare system burden.

References

1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–9.
2. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan. China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475–81.
3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20.
4. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020;395:1225–8.
5. Memish ZA, Perlman S, van Kerkhove MD, Zumla A. Middle East respiratory syndrome. Lancet. 2020;395:1063–77.
6. Rubio F, Amiel SA, Zimet P, Alberti G, Bornstein S, Eckel RH, et al. New-onset diabetes in COVID-19. N Engl J Med. 2020;383:789–90.
7. De Almeida-Pititto B, Dualib PM, Zajdenverg L, Rodrigues Dantas J, Dias de Souza F, Rodacki M, et al. Severity and mortality of COVID-19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. Diabetol Metab Syndr. 2020;12:75.
8. Totura AL, Whitmore A, Agnihothram S, Schäfer A, Katze MG, Heise MT, et al. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. mBio. 2015;6:e00638-15.
9. Iacobellis G. COVID-19 and diabetes: can DPP4 inhibition play a role? Diabetes Res Clin Pract. 2020;162:108125.
10. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020:e3319.
11. Lima MM, Nuccio JC, Villalobos M, Torres C, Balladares N. Sistema renina angiotensina y riesgo cardiometabólico. Rev Venez Endocrinol Metab. 2010;8:3–10.
12. Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong C, Turner AJ, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020;126:1456–74.
13. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382:1653–9.
14. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80.

15. South AM, Diz DJ, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318:H1084–90.

16. Jaeckel E, Manns M, von Herrath M. Viruses and diabetes. Ann N Y Acad Sci. 2002;958:7–25.

17. Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol. 2020;18:2128–30.

18. Zhu L, She Z, Cheng X, Qin J, Zhang X, Cai J, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31:1068–77.

19. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–74.

20. Sharma S, Ray A, Sadasivam B. Metformin in COVID-19; a possible role beyond diabetes. Diabetes Res Clin Pract. 2020;164:108183.

21. Pal R, Bhadada SK. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Res Clin Pract. 2020;163:108146.

22. Carboni E, Carta AR, Carboni E. Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19? Med Hypotheses. 2020;140:109776.

23. Gonzalez JS, Fisher L, Polonsky WH. Depression in diabetes: have we missing something important? Diabetes Care. 2011;34:236–9.

24. Bellido V, Pérez A. Consecuencias de la COVID-19 sobre las personas con diabetes. Endocrinol Diabetes Nutr. 2020;67:355–6.

25. Pérez A, Ramos A, Carreras G. Insulin therapy in hospitalized patients. Am J Ther. 2020;27:e71–8.

26. Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8:546–50.

27. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020;382:e102.

28. Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126:1671–81.

29. Riddle MC, Buse JB, Franks PW, Knowler WC, Ratner RE, Selvin E, et al. COVID-19 in people with diabetes: urgently needed lessons from early reports. Diabetes Care. 2020;43:1378–81.

30. Vivas D, Roldán V, Esteve-Pastor MA, Roldán I, Tello-Montoliu A, Ruiz-Nodar JM, et al. Recomendaciones sobre el tratamiento antitrombótico durante la pandemia COVID-19. Posicionamiento del grupo de trabajo de trombosis cardiovascular de la Sociedad Española de Cardiología. Rev Esp Cardiol. 2020;73:749–57.